Clinical trials: Locally Advanced Pancreatic Carcinoma
Locally Advanced Pancreatic Cancer
Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer
This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic…
- Trial name
- NCT06429904
- Testing
- Nimotuzumab+ NALIRIFOX
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Peking Union Medical College Hospital
Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Advanced pancreatic cancer is a highly aggressive and fatal disease with an extremely low 5-year survival rate. Combined chemotherapy is the mainstay of treatment for patients with unresectable advanced pancreatic cancer, and the…
- Trial name
- NCT05832892
- Testing
- surufatinib, KN046, gemcitabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan \& 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a…
- Trial name
- NCT01397019
- Testing
- Oxaliplatin, irinotecan, 5-FU & leucovorin
- Where
- 3 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Per Pfeiffer
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
Drugs used in chemotherapy work different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00047307
- Testing
- alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
The purpose of this study is to find out which doses of talimogene laherparepvec (T-Vec) can be given safely to participants with pancreatic cancer that is either too big to be taken out by surgery or has spread to other parts of…
- Trial name
- NCT03086642
- Testing
- Talimogene laherparepvec
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Karie D. Runcie, MD
Pancreatic Ductal Adenocarcinoma
S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer
This phase II clinical trial will enroll patients with newly-diagnosed locally-advanced pancreatic adenocarcinoma and adopt the Simon's two-stage optimum design.
- Trial name
- NCT03316326
- Testing
- Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Irinotecan
- Volunteers
- 35 people
- Sponsor
- National Taiwan University Hospital
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT04821284
- Testing
- Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil
- Where
- 2 sites in United States, Norway
- Volunteers
- 120 people
- Sponsor
- Flemming Forsberg
Pancreatic Cancer
Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel
This was a quality of life (QOL) study done in the context of a randomized trial in locally advanced or metastatic pancreatic cancer.
- Trial name
- QOLINPAC (NCT02106884)
- Testing
- Nab-paclitaxel, Gemcitabine
- Where
- 18 sites in Belgium
- Volunteers
- 146 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pancreatic Cancer
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
- Trial name
- ViP (NCT01601808)
- Testing
- Caprelsa (vandetanib)
- Where
- 14 sites in United Kingdom
- Volunteers
- 142 people
- Sponsor
- University of Liverpool
Pancreatic Cancer
CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer
Pancreatic ductal adenocarcinoma is a highly lethal cancer, and approximately 40% of patients present with non-metastatic locally advanced pancreatic cancer (LAPC) that is not suitable for surgical resection.
- Trial name
- PANCOSIL (NCT07595835)
- Testing
- CT-guided percutaneous intratumoural implantation of the OncoSil™ device
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- M.R. Meijerink
Pancreatic Cancer
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
- Trial name
- NCT00044031
- Testing
- G17DT Immunogen
- Volunteers
- 394 people
- Sponsor
- Cancer Advances Inc.
Pancreatic Cancer
Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00602602
- Testing
- bevacizumab, fluorouracil, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Cancer
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
The main purpose of this study is to see primarily if BYL719 is safe to be given to patients in combination with gemcitabine and nab-paclitaxel.
- Trial name
- NCT02155088
- Testing
- BYL719, Gemcitabine, (nab)-paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005591
- Testing
- cetuximab, gemcitabine hydrochloride
- Sponsor
- University of Alabama at Birmingham
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
- Trial name
- NCT06545942
- Testing
- MOMA-313, Olaparib
- Where
- 18 sites in United States, Spain and 1 more
- Volunteers
- 220 people
- Sponsor
- MOMA Therapeutics
Solid Tumor
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Trial name
- NCT06364696
- Testing
- ASP4396
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Pancreatic Cancer
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival rate has shown less than 10% due to its dismal prognosis.
- Trial name
- NCT05083780
- Testing
- Chlorphenesin Carbamate, Hydroxychloroquine
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Changhoon Yoo
Venous Thromboembolism, Metastatic Pancreatic Cancer
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
- Conditions
- Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- CATIQ P3 (NCT06861088)
- Testing
- Kinisoquin™
- Where
- 3 sites in United States
- Volunteers
- 480 people
- Sponsor
- Quercis Pharma AG
Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
Title: Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer.
- Conditions
- Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- NCT02035072
- Testing
- Gemcitabine, Oxaliplatin, Hypofractionated RT
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA)…
- Conditions
- Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- ODI-2001-01 (NCT07587827)
- Testing
- Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)
- Where
- 2 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Georges Francois Leclerc